[Objectives]To make simultaneous determination of vitamin K_(1)(VK_(1))and vitamin K_(2)(VK_(2),mainly MK-4,MK-7 and MK-9)in milk and dairy products.[Methods]A high performance liquid chromatographic method was develo...[Objectives]To make simultaneous determination of vitamin K_(1)(VK_(1))and vitamin K_(2)(VK_(2),mainly MK-4,MK-7 and MK-9)in milk and dairy products.[Methods]A high performance liquid chromatographic method was developed for the simultaneous determination of vitamin K_(1)(VK_(1))and vitamin K_(2)(VK_(2),mainly MK-4,MK-7 and MK-9)in milk and dairy products.After enzymatic digestion,the samples were extracted with hexane for VK_(1),MK-4,MK-7 and MK-9,subjected to gradient elution at excitation wavelength 243 nm and emission wavelength 430 nm,detected by high performance liquid chromatography with fluorescence detector and quantified by external standard method.[Results]The linearity of VK_(1),MK-4,MK-7 and MK-9 was good in the concentration range of 2.5-1000 ng/mL with the correlation coefficients greater than 0.999;The relative standard deviations(RSD)of VK_(1),MK-4,MK-7 and MK-9 in milk powder,liquid milk and yogurt were 1.32%-5.05%,1.10%-2.48% and 2.20%-3.47%,respectively;the recovery rates of VK_(1),MK-4,MK-7 and MK-9 at different levels in milk powder,liquid milk and yogurt were 81.1%-108%,81.8%-103%and 82.1%-99.2%,respectively.[Conclusions]The method is rapid,accurate,reproducible and capable of simultaneous determination of VK_(1),MK-4,MK-7 and MK-9.展开更多
目的 分析维生素K_(1)治疗血清异常凝血酶原(proteinin-duced by vitamin K absence or antagonistⅡ,PIVKA-Ⅱ)升高的不同肝病患者的疗效。方法 回顾性分析2017年1月~2020年7月在首都医科大学附属北京佑安医院收治的经维生素K_(1)治疗...目的 分析维生素K_(1)治疗血清异常凝血酶原(proteinin-duced by vitamin K absence or antagonistⅡ,PIVKA-Ⅱ)升高的不同肝病患者的疗效。方法 回顾性分析2017年1月~2020年7月在首都医科大学附属北京佑安医院收治的经维生素K_(1)治疗的PIVKA-Ⅱ升高的230例患者。其中肝癌组86例,亚急性肝衰竭组69例,胆汁淤积性肝病组75例,比较3组患者入院时的PIVKA-Ⅱ水平;3组患者应用维生素K_(1)治疗7天后PIVKA-Ⅱ和凝血酶原活动度(PTA)的变化。结果 原发性肝癌组患者PIVKA-Ⅱ值明显高于亚急性肝衰竭组、胆汁淤积性肝病组。亚急性肝衰竭组患者PTA水平明显低于原发性肝癌组、胆汁淤积性肝病组(P<0.001),经维生素K_(1)治疗后,原发性肝癌组PIVKA-Ⅱ、PTA水平较入院时变化不明显,差异无统计学意义(P>0.05)。胆汁淤积性肝病组PIVKA-Ⅱ明显下降,PTA明显升高,差异有统计学意义(P<0.001)。亚急性肝衰竭组,根据出院方式分为存活组及死亡组,死亡组患者PIVKA-Ⅱ下降不明显,PTA略有增加或无变化;存活组患者PIVKA-Ⅱ明显下降,PTA明显升高,差异有统计学意义(P<0.01)。结论 临床上对亚急性肝衰竭及胆汁淤积明显患者给予维生素K_(1)治疗,如果PIVKA-Ⅱ降低、PTA在短时间内增加,患者更有可能存活。展开更多
文摘[Objectives]To make simultaneous determination of vitamin K_(1)(VK_(1))and vitamin K_(2)(VK_(2),mainly MK-4,MK-7 and MK-9)in milk and dairy products.[Methods]A high performance liquid chromatographic method was developed for the simultaneous determination of vitamin K_(1)(VK_(1))and vitamin K_(2)(VK_(2),mainly MK-4,MK-7 and MK-9)in milk and dairy products.After enzymatic digestion,the samples were extracted with hexane for VK_(1),MK-4,MK-7 and MK-9,subjected to gradient elution at excitation wavelength 243 nm and emission wavelength 430 nm,detected by high performance liquid chromatography with fluorescence detector and quantified by external standard method.[Results]The linearity of VK_(1),MK-4,MK-7 and MK-9 was good in the concentration range of 2.5-1000 ng/mL with the correlation coefficients greater than 0.999;The relative standard deviations(RSD)of VK_(1),MK-4,MK-7 and MK-9 in milk powder,liquid milk and yogurt were 1.32%-5.05%,1.10%-2.48% and 2.20%-3.47%,respectively;the recovery rates of VK_(1),MK-4,MK-7 and MK-9 at different levels in milk powder,liquid milk and yogurt were 81.1%-108%,81.8%-103%and 82.1%-99.2%,respectively.[Conclusions]The method is rapid,accurate,reproducible and capable of simultaneous determination of VK_(1),MK-4,MK-7 and MK-9.
文摘目的 分析维生素K_(1)治疗血清异常凝血酶原(proteinin-duced by vitamin K absence or antagonistⅡ,PIVKA-Ⅱ)升高的不同肝病患者的疗效。方法 回顾性分析2017年1月~2020年7月在首都医科大学附属北京佑安医院收治的经维生素K_(1)治疗的PIVKA-Ⅱ升高的230例患者。其中肝癌组86例,亚急性肝衰竭组69例,胆汁淤积性肝病组75例,比较3组患者入院时的PIVKA-Ⅱ水平;3组患者应用维生素K_(1)治疗7天后PIVKA-Ⅱ和凝血酶原活动度(PTA)的变化。结果 原发性肝癌组患者PIVKA-Ⅱ值明显高于亚急性肝衰竭组、胆汁淤积性肝病组。亚急性肝衰竭组患者PTA水平明显低于原发性肝癌组、胆汁淤积性肝病组(P<0.001),经维生素K_(1)治疗后,原发性肝癌组PIVKA-Ⅱ、PTA水平较入院时变化不明显,差异无统计学意义(P>0.05)。胆汁淤积性肝病组PIVKA-Ⅱ明显下降,PTA明显升高,差异有统计学意义(P<0.001)。亚急性肝衰竭组,根据出院方式分为存活组及死亡组,死亡组患者PIVKA-Ⅱ下降不明显,PTA略有增加或无变化;存活组患者PIVKA-Ⅱ明显下降,PTA明显升高,差异有统计学意义(P<0.01)。结论 临床上对亚急性肝衰竭及胆汁淤积明显患者给予维生素K_(1)治疗,如果PIVKA-Ⅱ降低、PTA在短时间内增加,患者更有可能存活。
